Recursion Pharmaceuticals, Inc. (RXRX) Income Statement
RXRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRXRX revenue and net income
Where RXRX's revenue goes
2025Each bar shows an amount and its share of revenue. RXRX kept −863.4% of revenue as net income.
RXRX profit margins
RXRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +26.9% | +23.5% | +85.4% | — |
| Gross profit | −440.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RXRX quarterly EPS vs estimates
Recursion Pharmaceuticals beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.24).
RXRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $43.9M | $39.7M | $10.0M | $3.4M | $1.7M |
| Cost of revenue | $121.0M | $45.2M | $42.6M | $48.3M | $9.1M | $63.3M | $45.8M |
| Gross profit | −$46.3M | $13.6M | $1.3M | −$8.6M | $10.0M | $3.4M | −$44.1M |
| Research & development | $425.3M | $314.4M | $241.2M | $155.7M | $135.3M | $63.3M | $45.8M |
| Sales, general & admin | $176.6M | $178.2M | $110.8M | $81.6M | $57.7M | $25.3M | $19.0M |
| Total operating expenses | $601.9M | $492.6M | $351.3M | $237.1M | $192.8M | $88.0M | $64.2M |
| Operating income | −$648.1M | −$479.0M | −$350.1M | −$245.7M | −$182.8M | −$84.6M | −$62.4M |
| Interest income | $22.8M | $15.8M | $18.3M | $6.3M | $73,000 | $336,000 | $1.7M |
| Interest expense | $1.8M | $1.6M | $97,000 | $55,000 | $3.0M | $1.4M | $635,000 |
| Income before taxes | −$644.9M | −$464.8M | −$332.1M | −$239.5M | −$186.5M | −$87.0M | −$61.9M |
| Income taxes | −$136,000 | −$1.1M | −$4.1M | −$55,000 | −$8.4M | $876,000 | $646,000 |
| Net income | −$644.8M | −$463.7M | −$328.1M | −$239.4M | −$178.1M | −$87.0M | −$62.5M |
| EBITDA | −$559.4M | −$426.7M | −$307.6M | −$234.0M | −$174.4M | −$81.7M | −$58.3M |
| EPS (diluted) | −$1.48 | −$1.66 | −$1.57 | −$1.36 | −$1.20 | −$0.25 | −$2.84 |
| Gross margin | −62.0% | 23.1% | 2.9% | −21.7% | 100.0% | 100.0% | −2,577.3% |
| Operating margin | −867.9% | −814.1% | −797.8% | −619.3% | −1,827.8% | −2,479.2% | −3,649.4% |
| Net margin | −863.4% | −788.0% | −747.7% | −603.4% | −1,780.7% | −2,549.3% | −3,654.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $6.5M | $35.5M | $5.2M | $19.1M | $14.7M | $4.5M | $26.1M | $14.4M | $13.5M | $10.6M | $10.1M |
| Cost of revenue | $11.5M | $12.5M | $26.9M | $29.6M | $20.2M | $21.8M | $12.8M | $12.1M | $9.2M | $11.2M | $9.9M | $10.9M |
| Gross profit | −$3.8M | −$6.0M | $8.7M | −$24.4M | −$1.1M | −$7.1M | −$8.3M | $14.0M | $5.2M | $2.3M | $743,000 | −$775,000 |
| Research & development | $89.6M | $87.9M | $83.3M | $121.1M | $128.6M | $129.6M | $98.3M | $74.6M | $73.9M | $67.6M | $69.5M | $70.0M |
| Sales, general & admin | $41.5M | $34.6M | $33.7M | $41.6M | $46.7M | $54.6M | $77.2M | $37.8M | $31.8M | $31.5M | $30.5M | $29.2M |
| Total operating expenses | $131.1M | $122.5M | $117.0M | $147.8M | $175.2M | $184.3M | $175.5M | $112.4M | $105.7M | $98.7M | $99.7M | $98.8M |
| Operating income | −$135.0M | −$128.5M | −$108.3M | −$172.2M | −$176.2M | −$191.4M | −$183.8M | −$98.4M | −$100.5M | −$96.3M | −$98.9M | −$99.5M |
| Interest income | $5.3M | $6.0M | $6.2M | $5.5M | $5.4M | $5.6M | $4.6M | $3.8M | $3.3M | $4.0M | $4.5M | $5.0M |
| Interest expense | $309,000 | $350,000 | $11,000 | $833,000 | $480,000 | $508,000 | $605,000 | $553,000 | $394,000 | $20,000 | $26,000 | $25,000 |
| Income before taxes | −$131.0M | −$122.1M | −$108.1M | −$162.2M | −$171.9M | −$202.6M | −$178.9M | −$95.7M | −$98.1M | −$92.2M | −$97.1M | −$93.0M |
| Income taxes | −$1,000 | −$4.6M | $20,000 | $3,000 | — | −$158,000 | $7,000 | $167,000 | −$523,000 | −$779,000 | −$4.1M | $1.6M |
| Net income | −$131.0M | −$117.5M | −$108.1M | −$162.3M | −$171.9M | −$202.5M | −$178.9M | −$95.7M | −$97.5M | −$91.4M | −$93.0M | −$93.0M |
| EBITDA | −$112.5M | −$102.1M | −$88.6M | −$141.2M | −$147.6M | −$182.8M | −$165.3M | −$87.9M | −$88.7M | −$84.8M | −$89.5M | −$85.4M |
| EPS (diluted) | −$0.25 | −$0.22 | −$0.21 | −$0.36 | −$0.41 | −$0.50 | −$0.53 | −$0.34 | −$0.40 | −$0.39 | −$0.42 | −$0.43 |
| Gross margin | −49.8% | −93.0% | 24.4% | −471.8% | −5.5% | −48.0% | −183.6% | 53.7% | 36.1% | 17.2% | 7.0% | −7.7% |
| Operating margin | −1,759.7% | −1,985.6% | −304.8% | −3,327.6% | −922.5% | −1,297.9% | −4,073.8% | −377.1% | −698.0% | −714.1% | −931.2% | −985.4% |
| Net margin | −1,708.0% | −1,815.6% | −304.2% | −3,135.3% | −899.8% | −1,373.3% | −3,966.0% | −366.8% | −677.2% | −677.3% | −875.3% | −920.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RXRX's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RXRX financial results
In fiscal year 2025 (ended December 31, 2025), Recursion Pharmaceuticals reported revenue of $74.7 million, up 26.9% from the year before. It had a net loss of $644.8 million, a net profit margin of −863.4%. Diluted earnings per share came to −$1.48. Over five years revenue grew at an average rate of 85.4% a year.
See the RXRX stock overview for the latest quote and news, or the RXRX chart for price history and technical indicators.
RXRX income statement FAQ
What is Recursion Pharmaceuticals's annual revenue?
Recursion Pharmaceuticals reported total revenue of $74.7 million for fiscal year 2025, which ended on December 31, 2025. That was up 26.9% from $58.8 million the previous year.
Is Recursion Pharmaceuticals profitable?
No. Recursion Pharmaceuticals reported a net loss of $644.8 million in fiscal 2025, a net profit margin of −863.4%; its operating margin was −867.9%.
What is Recursion Pharmaceuticals's gross margin?
Recursion Pharmaceuticals's gross margin was −62.0% in fiscal 2025: for every $100 of revenue, Recursion Pharmaceuticals kept $-62 after the direct cost of its products and services.
How much does Recursion Pharmaceuticals spend on research and development?
Recursion Pharmaceuticals spent $425.3 million on research and development in fiscal 2025, 569.4% of revenue.
How fast is Recursion Pharmaceuticals growing?
Revenue grew 85.4% a year on average over the last five fiscal years, from $3.4 million to $74.7 million.
What are Recursion Pharmaceuticals's earnings per share?
Recursion Pharmaceuticals earned $-1.48 per diluted share in fiscal 2025, compared with $-1.66 a year earlier.
When will Recursion Pharmaceuticals report its next earnings?
Recursion Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens.
When does Recursion Pharmaceuticals's fiscal year end?
Recursion Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.